alcohol bladder cancer dose-response meta-analysis systematic review commercial or financial relationships that could be construed as a potential conflict of interest.

*Carcinoma Transitional Cell/surgery Cystectomy/adverse effects Humans Neoplasm Recurrence Local *Urinary Bladder Neoplasms/surgery

Adult Female *Hormones/adverse effects Humans Menopause Middle Aged Prospective Studies *Reproductive History Risk Factors *Urinary Bladder Neoplasms/epidemiology Bladder cancer Health Study Nurses’ females hormones reproductive factors

Humans *Laser Therapy/adverse effects Neoplasm Invasiveness Treatment Outcome Urinary Bladder Neoplasms/pathology/*surgery

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.

Antineoplastic Agents/*therapeutic use Biomarkers Tumor/*blood Humans Male Neoadjuvant Therapy/*methods Prognosis Urinary Bladder Neoplasms/blood/drug therapy/*pathology Biomarkers Bladder cancer Nac Neoadjuvant chemotherapy Systematic review Ucb

Crohn's disease bladder cancer inflammatory bowel diseases meta-analysis ulcerative colitis commercial or financial relationships that could be construed as a potential conflict of interest.

Biomarkers Tumor/*metabolism Estrogen Receptor alpha/*metabolism Estrogen Receptor beta/*metabolism GATA3 Transcription Factor/*metabolism Humans Prognosis Urinary Bladder Neoplasms/diagnosis/*metabolism Gata3 bladder cancer estrogen receptors immunohistochemistry tumour markers commercial or financial relationships that could be construed as a potential conflict of interest.

Biomarkers Tumor/*urine Humans Ribonuclease Pancreatic/*urine Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis/urine

Chemotherapy Adjuvant Humans Liquid Biopsy Muscles Neoplasm Invasiveness Prospective Studies *Urinary Bladder Neoplasms/drug therapy Cell-free DNA Circulating tumor cells Liquid biopsies Muscle-invasive bladder cancer Perioperative therapy

Administration Intravesical *Aneurysm Infected/therapy Aorta Humans *Mycobacterium bovis *Urinary Bladder Neoplasms/drug therapy

Animals Biological Availability Clinical Trials as Topic Flavonoids/pharmacology/*therapeutic use Flavonols/pharmacology/*therapeutic use Humans Inhibitory Concentration 50 Kaempferols/pharmacology/*therapeutic use Male Models Animal Prostatic Neoplasms/*drug therapy Urinary Bladder Neoplasms/*drug therapy bladder cancer fisetin kaempferol myricetin prostate cancer

Carcinoma Transitional Cell/*mortality/*pathology Humans Survival Rate Urinary Bladder Neoplasms/*mortality/*pathology carcinoma histology pathology survival transitional cell urinary bladder neoplasms

Administration Intravesical BCG Vaccine/*adverse effects/*therapeutic use Humans Meta-Analysis as Topic Randomized Controlled Trials as Topic *Systematic Reviews as Topic Urinary Bladder Neoplasms/*drug therapy

Carcinogenesis/genetics/*immunology/pathology *Genetic Predisposition to Disease Humans Inflammation/genetics/*immunology/pathology *Polymorphism Single Nucleotide Receptors Interleukin/*genetics Urinary Bladder Neoplasms/genetics/*immunology/pathology Bladder urothelial carcinoma Gene polymorphism Interleukin 17 Interleukin 23 Interleukin-23 receptor Natural killers Tumour-associated macrophages

Cystoscopy/*methods Feasibility Studies Humans Liquid Biopsy/methods Sensitivity and Specificity *Spectrum Analysis Raman Urinary Bladder/diagnostic imaging/*pathology Urinary Bladder Neoplasms/*diagnosis/pathology/urine Urine/cytology Bladder cancer Raman spectroscopy diagnosis meta-analysis optical

5-aminolaevulinic acid cystectomy cystoscopy hexylaminolaevulinate narrow-band imaging photodynamic diagnosis commercial or financial relationships that could be construed as a potential conflict of interest.

Disease-Free Survival *Dose Fractionation Radiation Humans Neoplasm Recurrence Local/epidemiology/pathology/*radiotherapy Radiation Dose Hypofractionation/*standards Risk Factors Treatment Outcome Urinary Bladder Neoplasms/epidemiology/pathology/*radiotherapy

Carcinoma Transitional Cell/mortality/surgery Cystectomy Disease-Free Survival Humans Nephroureterectomy Prognosis *Sex Factors Urinary Bladder Neoplasms/*mortality/*surgery Urologic Neoplasms/*mortality/*surgery carcinoma meta-analysis review [publication type] transitional cell urinary bladder neoplasms

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Clinical Trials as Topic Disease Progression Humans Neoplasm Metastasis *Neoplasm Recurrence Local Network Meta-Analysis Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology